Priority review for Takeda’s ultra-rare blood clot ERT; FDA to give another look at Ardelyx’s CKD drug

The FDA will review Takeda’s enzyme replacement therapy for an ultra-rare blood clotting disorder and decide whether to approve it within six months, the Japanese drugmaker said Wednesday.

The agency gave priority review to Takeda’s TAK-755, which was shown to reduce instances of low blood platelet…